business china genetech strategy - marketing

Perfect investment - Fast Blog Finder

Regeneron Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call ...

22.05.12

Regeneron Pharmaceuticals Inc. ( REGN ) Q4 2011 Earnings Call February 13, 2012 8:30 AM ET

Operator

Good morning ladies and gentlemen. Welcome to the Regeneron Pharmaceuticals Conference Call to discuss the fourth quarter and full-year 2011 financial results. My name is Latoya and I’ll be your coordinator for today. At this time, all participants are in a listen-only mode. We will conduct a question and answer session towards the end of the call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Dr. Aberman, Vice President of Strategy and Investor Relations for Regeneron. Please proceed, Dr. Aberman.

Dr. Michael Aberman

Thank you very much. Good morning and welcome to Regeneron Pharmaceuticals’ Fourth Quarter and Full-Year 2011 conference call. An archive of this webcast will be available on our website under Events and Presentations for 30 days.

Source: Seeking Alpha

Volvo Cars New Business Strategy China

Volvo Cars New Business Strategy presented in Beijing

Biotech SF: FDA approves Genentech's Actemra against rare Still's ...

by Ron Leuty

• This blog compiles San Francisco Bay Area biotech stories running in the San Francisco Business Times and Silicon Valley/San Jose Business Journal and their online sites. All stories link back to the San Francisco and San Jose sites, which may require subscriptions to see the full stories.

Source: Biotech SF: FDA approves Genentech's Actemra against rare Still's ...

business china genetech strategy - Read It!


ICIS chemical business ICIS chemical business

Technology & Engineering - 2009
He takes over from Niklaus Meier, who had been the interim CFO since Juerg Fedier left the company in 2008. ARTHUR LEVINSON Following Swiss pharmaceutical group Roches acquisition of US counterpart Genentech, Roche has announced the ...
The Wall Street journal, Index The Wall Street journal, Index

Business & Economics - 2006
... China; Venture capital companies; F 15 - C.5 IKEA AB Ikea Hits Home in China ; The Swedish Design Giant, Unlike Other ... AS: Seven-Story Beijing Outlet To Be Firm's Largest in Asia; [News] IKEA AB; BeijingChina; Market strategy; ...
Readings in Economic Sociology
384 pages 		Readings in Economic Sociology

Creator: Nicole Woolsey Biggart | Business & Economics - 2008-04-15
ties with diverse biotechs and health-care companies. The partial “parent” owner , Novartis of Switzerland, ... for example, spreads its search efforts globally, working with research institutes in France, Canada, China, Japan, ...
Publisher: Wiley-Blackwell
Gene therapy, prospective technology assessment in its societal context
252 pages 		Gene therapy, prospective technology assessment in its societal context

Creator: Christof Tannert | Medical - 2006-09-27
On the market In October 2003, according to Chinese and international response, Shenzhen SiBiono GeneTech made history. It became the first company approved to market a gene therapy medication. China's State Food and Drug Administration ...
Publisher: Elsevier Science
The New Players in Life Science Innovation, Best Practices in R&D from Around the World
340 pages 		The New Players in Life Science Innovation, Best Practices in R&D from Around the World

Creator: Tomasz F. Mroczkowski | Science - 2011-07-15
In this book, Tomasz Mroczkowski explains how China and other new economic powers are rapidly gaining leadership roles in the biosciences industries and thoroughly assesses the implications.
Publisher: Ft Pr

business china genetech strategy - News


Deals of the Week Is Not Ripe for Restructuring
The IN VIVO Blog (blog) - Apr 02, 2011
Deals of the Week Is Not Ripe for Restructuring The injectable product has received a Special Protocol Assessment from the FDA and will be tested in early-stage breast cancer patients not considered eligible for Genentech's Herceptin (trastuzumab) beginning next year.

Evotec Reports Full-Year 2010 Results: A Good Year With a Strong Start Into 2011
Stock Markets Review - Mar 24, 2011
Evotec's strategy is to build sustainable, performance-based drug discovery alliances. Consequently, Evotec focuses on high value, revenue generating partnerships with pharmaceutical and biotechnology companies. The Company is working with more than 70

Novartis makes strong start for the year
ITNews - Apr 19, 2011
The company thanks Mr Werlen for his dedication and contributions to the business over the last years. Delivering innovation, growth and productivity The long-term Novartis growth strategy is based on our focused, diversified portfolio.